 "Alembic Pharma, Torrent Pharma gain on USFDA nod for generic Abilify")
Shares of Alembic Pharmaceuticals and Torrent Pharmaceuticals have rallied by up to 11% in intra-day trade after the US Food and Drug Administration (FDA) approved the first generic versions of Abilify (aripiprazole).
Torrent Pharmaceuticals has rallied 11% to Rs 1,323 and Alembic Pharma surged 10% to Rs 498 on the National Stock Exchange (NSE) in intra-day trade.
Generic aripiprazole is an atypical antipsychotic drug approved to treat schizophrenia and bipolar disorder.
“Alembic Pharmaceuticals Ltd., Hetero Labs Ltd., Teva Pharmaceuticals and Torrent Pharmaceuticals Ltd. have received FDA approval to market generic aripiprazole in multiple strengths and dosage forms,” US FDA said in a news release. CLICK HERE TO READ FULL REPORT.
At 1044 hours, Alembic Pharma was up 6% at Rs 479, while Torrent Pharma by 5% at Rs 1,248 on the NSE. Sun Pharmaceuticals Industries was up nearly 1% at Rs 933.
Torrent Pharmaceuticals has rallied 11% to Rs 1,323 and Alembic Pharma surged 10% to Rs 498 on the National Stock Exchange (NSE) in intra-day trade.
Generic aripiprazole is an atypical antipsychotic drug approved to treat schizophrenia and bipolar disorder.
“Alembic Pharmaceuticals Ltd., Hetero Labs Ltd., Teva Pharmaceuticals and Torrent Pharmaceuticals Ltd. have received FDA approval to market generic aripiprazole in multiple strengths and dosage forms,” US FDA said in a news release. CLICK HERE TO READ FULL REPORT.
At 1044 hours, Alembic Pharma was up 6% at Rs 479, while Torrent Pharma by 5% at Rs 1,248 on the NSE. Sun Pharmaceuticals Industries was up nearly 1% at Rs 933.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%